Save Your Relationship: Get Better Sleep With the Scandinavian Sleep Method
Picture this: You've lain down for the evening, you're comfortable and cozy, you drift off... only to wake up in the middle of the night with no blankets because your partner has stolen them all while snoozing away next to you. Different people have different sleep needs, and a whopping one-third of Americans report that their partner has negatively affected their sleep. A recent CNET survey shows that 6 in 10 adults have considered changing their setup to ensure a good night's rest. The Scandinavian sleep method isn't a cure for snoring, but it can help if you're cuddling with a blanket hog.
If you're at your breaking point with sharing a bed but don't want to end up in a sleep divorce, trying a practice from Scandinavian countries might help. This solution may drastically improve your and your partner's sleep -- and relationship. So, how does the Scandinavian sleep method work? Here's what to know.
Best Duvet Covers of 2025
See at CNET
Also, don't miss our editors' favorite sleep tips, how to tackle anxiety before bed and whether tech can help you sleep better.
The Scandinavian sleep method is common practice in certain regions of the world, including Sweden, Norway, Denmark and other parts of Europe. The idea is simple: Instead of sharing a blanket at night, you and your partner each have your own. It's not about avoiding intimacy or sacrificing part of your relationship. It's about prioritizing your sleep needs so that both of you can wake up well-rested and energized.
Most people use two twin-size comforters or duvets for the Scandinavian sleep method. This sleeping style typically works best on king mattresses, which give the separate blankets the most room, but queen mattresses work fine for most people.
Traditionally, you forgo the shared flat sheet for this. If you're like me and love flat sheets, you can always opt for two flat sheets in addition to separate blankets. There's no right or wrong way to do it.
The main benefits of the Scandinavian sleep method are more quality sleep and less strain on your relationship. Getting restful shuteye positively impacts overall health and wellness, from immune support to coping with daily stressors.
Promotes better sleep quality
Reduces the number of sleep disturbances
Allows for an individualistic sleep setup
Encourages better temperature regulation
Can create a more relaxing environment
Co-sleeping; don't have to resort to sleep divorce
Can help prevent unnecessary stress or strain in your relationship
Sharing a comforter with your partner might not be the best option for your needs, and that's OK. Sleep is inherently a single-player sport. It's not something you are required to share with your partner. For many, sharing a blanket might not be the best move for your sleep quality. One study found that sharing comforters results in 30% more interrupted sleep.
By each having their own blanket, the half-asleep tug-of-war battle is eliminated, and so are all the times you wake up because you're cold and blanketless. You also can adjust positions at night without worrying about affecting your partner.
Remember that the Scandinavian sleep method isn't reserved just for those who live with a blanket hog. It's a good option for anyone who tosses and turns or has a different sleeping pattern that may wake up their partner.
For a visual representation, watch Swedish NYT bestselling author and popular YouTuber Cecilia Blomdahl explain the Scandinavian sleep method from her remote cabin in Svalbard, near the North Pole.
Comforters and duvets are fluffy blankets that come in various thicknesses and materials for temperature regulation. A comforter is one complete piece, while a duvet is meant to be inserted into a cover or coverlet.
Duvet covers are interchangeable, so you can easily alter the look of your bed without buying a whole new comforter set. Duvets are also easier to clean because you can remove and wash the cover. Comforters are easier to use because they're one blanket with no cover. They're usually quilted or stitched so that the material inside is secure and evenly distributed. You won't have "bunching up" issues with comforters like you might with a duvet in its cover.
For the Scandinavian sleep method, both duvets and comforters work great as long as each partner uses their own. If I had to choose between the two options, I would recommend comforters for their simplicity. Using two duvets means you'll have double the work of reinserting them into their respective covers every time you wash the bedding, which can be awkward and time-consuming. Ultimately, it's up to your preferences and whatever will help you and your partner sleep best.
When my boyfriend is asleep, he turns into an (almost literal) pool of lava, kicking off the blanket to cool down. I'm not like that; I like to burrow into my blanket all night.
Having two blankets allows for personalization in temperature. Temperature is essential when we sleep; it triggers when we fall asleep and wake up. Getting too warm or too cold will interrupt our circadian rhythm.
If your partner is a hot sleeper who only wants to use a sheet while you like to wrap in a comforter burrito, then you have that freedom with separate bedding. You have the choice to use a quilt, fuzzy blanket or light duvet, while your partner could use nothing at all -- or something more substantial, like a weighted blanket.
Throughout their couple's mattress testing series, CNET video producer Dillon and writer Aly have discussed resorting to the Scandinavian sleep method a few times.
"If we anticipate one of us will likely toss and turn for whatever reason, Dillon and I use the Scandinavian sleep method. We keep extra comforters and blankets in the bedroom to grab if one person is being annoying -- whether hogging the blankets or kicking them all off. It makes a huge difference," Aly says.
If your sleep problems are due to your or your partner's underlying sleep disorder, using two blankets won't solve everything, although it can help protect you from additional sleep disturbances. Sleep is essential for health. When we sleep, our bodies go into recharge mode. Getting enough sleep will result in better memory and concentration, a stronger immune system and better heart health. If you're not getting enough sleep at night, it's important to figure out why.
Read more: Best Mattresses for Good Sleep
It may be as simple as using the wrong pillow or sleeping on a mattress that's too old and needs to be replaced. It could be something more serious like sleep apnea or insomnia that can significantly disturb your sleep. It's best to talk to your doctor if you're not sleeping well to explore the underlying causes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
CKD Therapy Unchanged by Patient and PCP Nudge Letters
VIENNA — Sending 'nudge' letters to patients with chronic kidney disease (CKD) or their general practitioners had no impact on their likelihood of receiving guideline-directed medical care, suggested a prescription analysis of over 22,000 Danish adults with CKD. METHODOLOGY: NUDGE-CKD included all Danish individuals aged 18 years or older on August 19, 2024, who had received a diagnosis of CKD in the previous 5 years during at least one hospital encounter and who were enrolled in the Danish governmental electronic letter system, which has 95% coverage. It also included all Danish general practices contactable via electronic letter that had at least one patient with CKD on their list. For patients, the letter highlighted the potential benefits of kidney and heart health and encouraged a discussion of treatment options, while for general practitioners, the letter focused on the latest treatment guidelines. In the patient arm of the study, 22,627 individuals were randomly assigned to receive a letter (n = 11,223) or no letter (n = 11,394). The average age was 71 years, and approximately 36% were women. For the practitioner arm, 1540 general practices, caring for 28,069 patients with CKD, were assigned to receive a letter (774 practices caring for 13,959 patients) or usual care (766 practices caring for 14,110 patients). The average patient age was 73 years, and approximately 39% were women. Both patients and practices were followed up for 6 months (until February 19, 2025), with the primary endpoint the number of filled prescriptions for a renin-angiotensin system inhibitor (RASi) or SGLT2 inhibitor (SGLT2i). TAKEAWAY: The patient analysis revealed that there was no significant difference in prescriptions of RASi or SGLT2i between those who received a nudge letter and those who did not, at a relative risk of 0.99 ( P = .21). = .21). Very similar results were seen on the general practice analysis, at a relative risk of a RASi or SGLT2i prescription with a nudge letter vs usual care of 0.99 ( P = .41). = .41). No significant differences were seen on the subgroup analysis and when looking at the time to prescription for new users, and there was no interaction between the patient and general practice results ( P = .85). IN PRACTICE: The trial was the 'largest provider-targeted implementation study to date evaluating a scalable, low-cost strategy to improve the use of guideline-related medical therapy in CKD' and the 'first large-scale trial of a digitally delivered strategy targeting patients with a common chronic condition,' said the study presenter. 'While the results were neutral, they may provide valuable insights for future efforts,' he concluded. SOURCE: The research was conducted by Kristoffer Grundtvig Skaarup, MD, Department of Cardiology, Copenhagen University Hospital — Herlev and Gentofte, Denmark, and colleagues, and described over two presentations at the 62nd European Renal Association (ERA) Congress 2025 on June 7. LIMITATIONS: Skaarup pointed out that, on the general practice side, the intervention was a 'one-time letter…and not linked to specific patients, which may have limited its lasting impact.' He suggested that more integrated approaches timed to clinical encounters or even embedded into existing clinical workflows closer to when prescription decisions are made may be more effective in primary care. Although most patients reported reading the letter, Skaarup said that few acted on it, potentially due to its general, non-personalized content, with no explicit medical therapy recommendations, which may limit its perceived relevance or urgency. DISCLOSURES: No external funding was obtained for the trial. Skaarup received funding through a research grant from the Danish Cardiovascular Academy, which is supported by the Novo Nordisk Foundation and the Danish Heart Foundation. No relevant financial relationships were declared. Liam Andrew Davenport, MA (Hons), is a UK-based medical journalist and writer with more than 20 years' experience. He studied medical sciences and anthropology at Emmanuel College, Cambridge, England.
Yahoo
2 hours ago
- Yahoo
BioInvent Announces Promising Phase 1 Data of BI-1206 in Combination with KEYTRUDA(R) (pembrolizumab) in Solid Tumors
The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors with one complete response, one long-lasting partial response, and 11 patients with stable disease. Based on this promising data, BioInvent plans to initiate Phase 2a expansion cohorts to treat patients with advanced or metastatic non-small cell lung cancer (NSCLC) or uveal melanoma, in the front line in combination with KEYTRUDA® (pembrolizumab). Patient enrollment is expected to begin H2 2025. LUND, SE / / June 11, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced updated, positive Phase 1 data of intravenous (IV) and subcutaneous (SC) BI-1206 in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in heavily pre-treated patients with solid tumors. Based on the encouraging data, the company intends to expand its investigation of BI-1206 SC in combination with pembrolizumab in earlier lines of treatment, by initiating a Phase 2a study arm with focus on first-line patients with advanced or metastatic NSCLC and uveal melanoma. The Phase 2a study is planned to be initiated during H2 2025. The updated Phase 1 data in heavily pre-treated patients - including several lines of IO agents - show encouraging clinical activity of the combination, with one patient with metastatic cutaneous melanoma experiencing a complete response (CR), one patient with metastatic uveal melanoma achieving a long-lasting partial response (PR) and 11 patients experiencing stable disease (SD) out of a total of 36 evaluable patients. The product was well-tolerated, enabling continued dose expansion exploring the use of higher dose levels. The trial is part of BioInvent's strategy to transition from IV dosing to SC formulation for BI-1206 allowing slower systemic entry and prolonged time on target to enhance the products therapeutic impact and improve safety and tolerability of the combination. The Phase 1 data in solid tumors corroborate preclinical findings that BI-1206 significantly enhances the effect of anti-PD-1. Based on this evidence, MSD and BioInvent have agreed to further investigate the synergies between BI-1206 and pembrolizumab in earlier lines of treatment. The upcoming Phase 2a study of BI-1206 in combination with pembrolizumab is planned to be performed in treatment-naïve patients with NSCLC and uveal melanoma. "We are highly encouraged by the clinical responses emerging from our solid tumor program which support the broad utility of combining subcutaneous BI-1206 with pembrolizumab in a range of solid tumors," said Martin Welschof, Chief Executive Officer of BioInvent. "The strong signals we have observed in heavily pre-treated patients support the idea that BI-1206 could be used to improve the activity of pembrolizumab across different tumor types, and we therefore look forward to initiating our Phase 2a study in the high unmet medical need of non-small cell lung cancer." KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. ###About NSCLC and combination treatment with targeting FcyRIIBNSCLC is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. While checkpoint inhibitors are widely accepted and can produce durable responses in NSCLC, the overall response rate remains low, rarely exceeding 25%. A common resistance mechanism in cancer is the binding and degradation of therapeutic antibodies against PD-1 such as pembrolizumab by FcγRIIB expressing immune cells. Therefore, based on preclinical and early clinical data, the company believes that resistance or lack of response to anti-PD-1 treatment may be overcome by FcγRIIB blockade in particular in subjects who have never been exposed to anti PD-1 agents. About BI-1206BI-1206 is one of BioInvent's lead drug candidates and is developed to re-establish the clinical effect of existing cancer treatments such as pembrolizumab and rituximab. The drug candidate is evaluated in two separate clinical programs, one for the treatment of solid tumors and one for the treatment of non-Hodgkin's lymphoma (NHL, a type of blood cancer). BI-1206 in solid tumorsClinical Phase 1/2a study with BI-1206 in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in heavily pre-treated patients with solid tumors (NCT04219254) is ongoing. The concluded Phase 1 dose escalation study in heavily pre-treated patients shows encouraging clinical activity of the combination, including one CR in metastatic melanoma, one PR in uveal melanoma and 11 patients experiencing SD out of a total of 36 evaluable patients. The product was well-tolerated, enabling continued dose expansion exploring the use of higher dose levels. For further details, please refer to the ASCO 2024 poster on the company web site: Out of the patients with stable disease as best response, one patient with long-lasting metastatic melanoma, who had previously progressed on nivolumab treatment, remained a stable disease throughout the two-year study duration with BI-1206 and pembrolizumab. The planned Phase 2a study of BI-1206 in combination with pembrolizumab for treatment-naïve patients with NSCLC and uveal melanoma consists of two parts: a signal seeking phase and a dose optimization phase. In the first signal seeking phase, up to 30 NSCLC and 12 uveal melanoma patients will receive fixed doses of BI-1206 and pembrolizumab every 21 days for three treatment cycles. Patients showing clinical benefit by Week 9 can continue therapy for up to 32 additional cycles, while those with disease progression will not proceed further. About BioInventBioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at For further information, please contact:Cecilia Hofvander, VP Investor RelationsPhone: +46 (0)46 286 85 50Email: International AB (publ)Co. Reg. No.: 556537-7263Visiting address: Ideongatan 1Mailing address: 223 70 LUNDPhone: +46 (0)46 286 85 The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release. Attachments BioInvent Announces Promising Phase 1 Data of BI-1206 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors SOURCE: BioInvent International View the original press release on ACCESS Newswire Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
CNET
19 hours ago
- CNET
Cutting Back on Coffee Is Hard -- Painful, Even. Here's How to Make It Easier
If you like to start your day with a warm cup of coffee or green tea for an energy boost, you're not alone. The National Coffee Association estimates that 66% of US adults drink coffee daily. Rest assured, I'm part of that percentage -- just thinking about my morning cup of joe motivates me to roll out of bed. Caffeine is a powerful drug. In fact, it's the most popular psychoactive drug in the world -- but unlike other psychoactive drugs, it's largely unregulated. People who habitually drink beverages with caffeine can develop a dependence on it, both physically and emotionally. Giving up that precious relationship is no easy feat. If done too quickly, it can be uncomfortable and even painful. If you regularly drink coffee, tea, energy drinks or soda, you may experience side effects or withdrawal symptoms when slashing your consumption. Here's everything you need to know about your caffeine intake, with expert tips for cutting back safely. How much caffeine should you consume? Most experts agree that the daily recommended caffeine limit for the average adult is 400 milligrams, which is roughly equivalent to four cups of brewed coffee. However, this recommendation may vary based on factors such as age and health conditions. According to Gabriella Nowicki, an oncology dietitian at Rebecca Bitzer & Associates, "Age, gender, weight and medical status affect this recommendation. Children under 12 should have no caffeine, while children under 18 should keep their intake lower than 100 milligrams. Pregnant individuals are advised to limit caffeine to under 200 milligrams a day." Certain medical conditions may also require people to reduce their caffeine intake. "Those with uncontrolled high blood pressure and heart arrhythmias should limit caffeine. Those living with IBS, anxiety, GERD and sleep disorders might benefit from reducing overall caffeine consumption," Nowicki explained. Whether your go-to drink is a refreshing soda or a hot cup of coffee, our beloved beverages can be hard to part with. Tongpatong/Getty Images What are the symptoms of caffeine withdrawal? According to the US Food and Drug Administration, caffeine withdrawal is not typically considered dangerous, unlike withdrawal from other drugs such as alcohol or opioids. However, the side effects of abruptly quitting caffeine can be downright unpleasant. Common withdrawal symptoms include: Headaches or migraines Fatigue or brain fog Difficulty concentrating Nausea Increased appetite Irritability Tips for cutting back on caffeine There are effective ways to cut back on your caffeine consumption without experiencing harsh withdrawal side effects. Here are some simple tips to help. 1. Don't quit cold turkey The top recommendation is to avoid abruptly stopping your intake -- don't go from 100 to zero. Health experts agree it's best to wean yourself off by gradually reducing your daily consumption. "Like anything, start slow. If you regularly consume four cups of coffee daily, cut back to three. If you're having a hard time cutting down on the volume of coffee, do half-caffeinated," Nowicki told CNET. According to the Cleveland Clinic, it's best to decrease caffeine intake over a few weeks to minimize withdrawal symptoms and make lasting changes to your habit. Try alternating between regular coffee and decaf or cutting back from four cups a day to three, then two, and so on. 2. Stay hydrated This tip may seem like a no-brainer, but it's crucial nonetheless: drink water, especially if you're on the verge of a headache. Prioritize your hydrating habits, as dehydration can lead to symptoms similar to caffeine withdrawal, including headaches and fatigue. To make it easier to shift from a coffee-drinking habit to a water-drinking habit, try having water with each meal and snack, or keep a bottle of water handy to sip on throughout your workday. Staying hydrated is especially important in the mornings when you would normally grab the coffee mug. We often wake up dehydrated after sleeping because our bodies naturally lose fluids during this time through processes like breathing and sweating. Even if you're not cutting back on coffee or soda, water should be the first thing you reach for. Waking up thirsty or with a dry mouth is common. Drinking water first can help restore your hydration levels off the bat. Skynesher/Getty Images Read more: Thirsty? 7 Reasons Why You Should Hydrate More 3. Prioritize sleep Caffeine helps keep us alert and awake, which is precisely why you should avoid it well before bedtime. Ideally, your caffeine consumption should end at least 10 hours before going to sleep -- otherwise, it can affect your sleep-wake cycle, making it harder to fall and stay asleep. Nowicki recommends having a cutoff time of 12 hours before hitting the hay. If you're not getting quality rest, you'll wake up feeling groggy, making that extra cup of coffee all the more tempting. 4. Eat good food In addition to drinking more water and getting better rest, choosing nutrient-dense foods will make you feel more alert. Certain foods energize us more effectively than others, such as oats, avocados, berries, nuts, seeds and yogurt. Eating these nutrient-rich foods in the morning can give you the boost you need sans caffeine. Additionally, prioritizing complex carbohydrates, such as whole grains and starchy vegetables, over simple carbs can help maintain steadier energy levels throughout the day. Read more: The Best Energy-Boosting Foods, According to Experts 5. Get some exercise It may seem counterintuitive, but exercise can naturally boost your energy. Even a quick walk can boost oxygen circulation, stimulate the production of feel-good hormones like serotonin and release chemical endorphins that make us more alert. Regular exercise, in turn, promotes better sleep quality -- helping you feel less dependent on your caffeinenated companion. So, the next time you feel a pull toward that soda or fifth cup of coffee, try getting up and moving around instead. 6. Swap with other drinks "Sometimes we just crave a ritual to drink something other than water. Try herbal teas, mocktails or mushroom coffee to shake up the ritual," Nowicki suggested. If you're a soda drinker, consider substituting it with another cold and fizzy beverage. Prebiotic sodas are popular soft drink alternatives, often containing less caffeine and sugar than their pop counterparts. Consider infusing your water with fruits or herbs for a refreshing caffeine replacement."Herbal or spicy tea, like ginger or peppermint, can stimulate the senses. Drinks with B vitamins or magnesium can support natural energy," Nowicki continued. Many beverage brands now offer coffee alternatives that can simulate the experience of sipping your aromatic cup of coffee with far less caffeine. One example is Mud/Wtr, which includes ingredients such as cacao, masala chai, functional mushrooms and only 35 milligrams of caffeine. The following chart shows the average caffeine content for various beverages, according to the US FDA. Caffeinated beverages compared Beverage Average amount of caffeine per 12 fluid ounces Soda or caffeinated soft drink 23 to 83 milligrams Coffee (brewed) 113 to 247 milligrams Coffee (drip) 140 to 180 milligrams Decaf coffee 2 to 18 milligrams Green tea 37 milligrams Black tea 71 milligrams Energy drink 41 to 246 milligrams Pre-workout 150 to 300 milligrams It's important to note that each drink's caffeine amount varies drastically depending on the brewing method and brand. Energy drinks, especially those marketed as "extra strength," have a lot more caffeine -- for example, 5-Hour Energy has 230 milligrams in one 2-ounce shot. Always read the nutrition labels first if you're tracking and limiting your caffeine consumption. What to do if you're having withdrawal If it's too late, and you're experiencing headache, brain fog, nausea or other symptoms while reading this, Nowicki has some suggestions for alleviating those annoying side effects: Take a short nap (around 20 minutes) Try smelling coffee if someone has a pot on already Get some sunshine and fresh air Take a short walk Stay well hydrated Caffeine withdrawal symptoms vary from person to person. They typically begin to appear 12 to 24 hours after your last sip and can last up to a week or longer. If you're experiencing extreme symptoms that are unmanageable, be sure to consult a healthcare professional. The bottom line The limit on caffeine does, indeed, exist. According to Nowicki, if you're consuming too much caffeine, you may experience side effects such as: GI upset (reflux, loose stool or stomach cramping) Headaches or migraines Poor appetite Jitteriness Anxiety The best way to avoid withdrawal symptoms is by reducing your caffeine intake slowly -- don't quit cold turkey. Gradually reduce the amount you drink daily, preferably over a few weeks, and swap out your caffeinated beverages with other healthy alternatives. Don't forget to drink lots of water, prioritize sleep and eat a nutrient-rich diet. If you have questions or concerns, consult your primary care provider before making any drastic changes.
